Bitcoin Cash (BCH) perpetual futures have recently become available on regulated European Economic Area (EEA) exchanges like OKX and Kraken, moving from offshore-only venues. These regulated contracts feature capped leverage (up to 10x), standardized funding intervals every 8 hours, and fixed five-year cash settlement terms, which differ from the higher leverage and perpetual nature of offshore contracts. This shift allows more institutional and professional traders within Europe to access BCH derivatives under compliance rules, enabling hedging and relative-value trading strategies. Liquidity is significant but varies by venue, requiring careful execution and risk management. The regulated environment also brings clearer reporting and tax implications, making BCH and other legacy fork assets more accessible for diversified trading within legal frameworks.
The global therapeutic apheresis market, valued at $3.84 billion in 2025, is projected to grow to $8.94 billion by 2035 at a 7.9% CAGR. Growth is fueled by rising chronic and autoimmune diseases, advances in automated apheresis technology, and expand...
Aduro Clean Technologies completed a private placement raising C$9.16 million by selling 431,884 shares at C$21.20 each. The funds will support technology development, marketing activities, working capital, and general corporate needs. The offering w...
Aduro Clean Technologies completed a private placement raising approximately C$9.16 million by selling 431,884 common shares at C$21.20 each. The funds will support technology development, marketing, working capital, and general corporate purposes. T...
Mesoblast Limited has drawn $50 million from a new five-year loan facility provided by a shareholder, replacing higher-cost short-term debt. This move strengthens Mesoblast's balance sheet by lowering interest costs and removing short-term obligation...
HUTCHMED announced positive Phase II trial results for fanregratinib in treating advanced intrahepatic cholangiocarcinoma (ICC) with FGFR2 fusion/rearrangement. The study showed a 42.5% objective response rate and median overall survival of 16.6 mont...
